/CORT
CORT Stock - Corcept Therapeutics Incorporated
Healthcare|BiotechnologyNASDAQ
$83.76+2.72%
+$2.22 (+2.72%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.82
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).77
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+13.4%upside
Target: $94.98
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CORT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$82.92 – $84.60
TARGET (TP)$95.00
STOP LOSS$77.06
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.20
52W High$117.33
52W Low$49.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $675.04M | $482.38M | $401.86M | $365.98M | $353.87M |
| Gross Profit | $664.16M | $475.89M | $396.47M | $360.70M | $348.29M |
| Gross Margin | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% |
| Operating Income | $136.95M | $107.28M | $112.63M | $124.48M | $128.20M |
| Net Income | $139.73M | $106.14M | $101.42M | $112.51M | $106.01M |
| Net Margin | 20.7% | 22.0% | 25.2% | 30.7% | 30.0% |
| EPS | $1.35 | $1.02 | $0.95 | $0.97 | $0.92 |
Company Overview
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
50%
Hold / Neutral
3
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish3 Neutral/Bearish
Price Targets
$30
Average Target
↓ 64.0% Downside
Now
$22
Low
$30
Average
$38
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | UBS | Initiation | Neutral | - |
| November 18th 2025 | Wolfe Research | Initiation | Peer Perform | - |
| November 6th 2023 | Truist | Upgrade | Buy | $38← $29 |
| April 11th 2023 | SVB Securities | Initiation | Market Perform | $25 |
| April 4th 2023 | Piper Sandler | Initiation | Overweight | $27 |
| February 15th 2023 | Jefferies | Downgrade | Hold | $22← $35 |
| August 1st 2022 | Truist | Downgrade | Hold | $30 |
| July 27th 2022 | Jefferies | Upgrade | Buy | $35← $21 |
| June 27th 2022 | Canaccord Genuity | Resumed | Buy | $34← $30 |
Earnings History & Surprises
CORTBeat Rate
61%
Last 18 quarters
Avg Surprise
+11.3%
EPS vs Estimate
Beats / Misses
11/5
2 met exactly
Latest EPS
$0.16
Q4 2025
EPS Surprise History
Q1 24
+7.7%
$0.28vs$0.26
Q2 24
+13.6%
$0.25vs$0.22
Q3 24
+39.1%
$0.32vs$0.23
Q4 24
+46.4%
$0.41vs$0.28
Q1 25
-29.7%
$0.26vs$0.37
Q2 25
0.0%
$0.17vs$0.17
Q3 25
+26.1%
$0.29vs$0.23
Q4 25
-11.1%
$0.16vs$0.18
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.27 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.18 | $0.16 | -11.1% | ✗ MISS |
Q3 2025 | Jul 31, 2025 | $0.23 | $0.29 | +26.1% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $0.17 | $0.17 | 0.0% | = MET |
Q1 2025 | Feb 26, 2025 | $0.37 | $0.26 | -29.7% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $0.28 | $0.41 | +46.4% | ✓ BEAT |
Q3 2024 | Jul 29, 2024 | $0.23 | $0.32 | +39.1% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $0.22 | $0.25 | +13.6% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $0.26 | $0.28 | +7.7% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.22 | $0.28 | +27.3% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $0.15 | $0.25 | +66.7% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.19 | $0.14 | -26.3% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $0.23 | $0.14 | -39.1% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $0.23 | $0.30 | +30.4% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.24 | $0.24 | 0.0% | = MET |
Q2 2022 | May 5, 2022 | $0.24 | $0.20 | -16.7% | ✗ MISS |
Q1 2022 | Feb 15, 2022 | $0.22 | $0.26 | +18.2% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.20 | $0.24 | +20.0% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.16 | $0.21 | +31.2% | ✓ BEAT |
Latest News
UBS Initiates Coverage On Corcept Therapeutics with Neutral Rating, Announces Price Target of $95
➖ NeutralBenzinga•Dec 16, 2025, 01:39 PM•Also:
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $145 Price Target
📈 PositiveBenzinga•Nov 25, 2025, 12:04 PM
Wolfe Research Initiates Coverage On Corcept Therapeutics with Peer Perform Rating
➖ NeutralBenzinga•Nov 18, 2025, 05:22 PM
CORT stock has given up its prior loss. Corcept Therapeutics shares were trading lower after the company reported worse-than-expected Q3 sales results and cut its FY25 sales guidance below estimates.
📉 NegativeBenzinga•Nov 5, 2025, 02:37 PM
Corcept Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results and cut its FY25 sales guidance below estimates.
📉 NegativeBenzinga•Nov 5, 2025, 02:03 PM
Corcept Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results and cut its FY25 sales guidance below estimates.
📉 NegativeBenzinga•Nov 4, 2025, 09:43 PM
Corcept Therapeutics Lowers FY2025 Sales Guidance from $850.000M-$900.000M to $800.000M-$850.000M vs $852.721M Est
📉 NegativeBenzinga•Nov 4, 2025, 09:12 PM
Corcept Therapeutics Q3 EPS $0.16 Beats $0.14 Estimate, Sales $207.638M Miss $218.526M Estimate
➖ NeutralBenzinga•Nov 4, 2025, 09:11 PM
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $145 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 02:01 PM
Reported Sunday, Corcept Highlights ROSELLA Late-Breaker: Relacorilant Plus Nab-Paclitaxel Improves PFS And OS In Platinum-Resistant Ovarian Cancer
📈 PositiveBenzinga•Oct 20, 2025, 07:37 AM
Corcept Therapeutics shares are trading higher after the company announced it submitted a Marketing Authorization Application to the European Medicines Agency for relacorilant to treat patients with platinum-resistant ovarian cancer. The company terminated its distribution agreement with Optime Care.
📈 PositiveBenzinga•Oct 15, 2025, 04:08 PM
Corcept Submits Marketing Authorization Application To European Medicines Agency For Relacorilant For Patients With Platinum-Resistant Ovarian Cancer
📈 PositiveBenzinga•Oct 14, 2025, 12:08 PM
In An SEC Filing On Tuesday, Corcept Therapeutics Said On Friday, The Company Announced The Termination Of The Distribution Agreement With Optime Care-8K
📉 NegativeBenzinga•Oct 14, 2025, 10:47 AM
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $145 Price Target
📈 PositiveBenzinga•Oct 10, 2025, 11:06 AM
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Maintains $140 Price Target
📈 PositiveBenzinga•Sep 25, 2025, 12:32 PM•Also:
Corcept Therapeutics To Present New Data From Pivotal Phase 3 ROSELLA Trial Of Relacorilant Plus Nab-Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer At 2025 ESMO
📈 PositiveBenzinga•Sep 22, 2025, 06:31 PM
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $140
📈 PositiveBenzinga•Sep 10, 2025, 02:21 PM•Also:
FDA Accepts Corcept's NDA For Relacorilant In Platinum-Resistant Ovarian Cancer, Sets PDUFA Date For July 11, 2026
📈 PositiveBenzinga•Sep 10, 2025, 12:08 PM
Frequently Asked Questions about CORT
What is CORT's current stock price?
Corcept Therapeutics Incorporated (CORT) is currently trading at $83.76 per share. The stock has moved +2.72% today.
What is the analyst price target for CORT?
The average analyst price target for CORT is $95.00, based on 1 analyst.
What sector is Corcept Therapeutics Incorporated in?
Corcept Therapeutics Incorporated operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CORT's market cap?
Corcept Therapeutics Incorporated has a market capitalization of $8.81 billion, making it a mid-cap company.
Does CORT pay dividends?
No, Corcept Therapeutics Incorporated does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
AXSM
Axsome Therapeutics, Inc.
$152.65
Mkt Cap: $7.7B
CAI
Caris Life Sciences, Inc.
$27.94
Mkt Cap: $7.9B
CYTK
Cytokinetics, Incorporated
$62.72
Mkt Cap: $7.5B
HALO
Halozyme Therapeutics, Inc.
$67.35
Mkt Cap: $7.9B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MRUS
Merus N.V.
$97.01
Mkt Cap: $7.4B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
Explore stocks similar to CORT for comparison